UNSPSC 51321708: Atorvastatin calcium trihydrate

This classification denotes a hmg-coa reductase inhibitor with the molecular formula 2C33H34FN2O5.Ca.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48A5M73Z4Q, chemically known as 1h-pyrrole-1-heptanoic acid, beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (r-(r*,r*))- but more generally known as atorvastatin calcium, which bears US NIH Compound Identifier 60822.

UNSPSC 51321708 Atorvastatin calcium trihydrate is a Commodity code that designates a single statin pharmaceutical product used in emergency medical response and state-administered pharmacy benefit programs. State and local governments soliciting under this code are purchasing specific prescription medications and over-the-counter products through emergency services procurement (fire rescue departments), state health agencies managing pharmacy benefits for Medicaid and state employee populations, and multistate cooperative purchasing alliances. The Tampa Fire Rescue procurement (IFB 26P00188) illustrates the emergency medical supply use case, though that specific bid specified other advanced life support agents rather than atorvastatin; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products represents the broader state and health-plan procurement model where atorvastatin would be included among many generic statin formulations sourced through authorized wholesalers. Issuing bodies include city fire departments, state health and human services commissions, and cooperative purchasing vehicles serving multiple state and local jurisdictions. Vendors must maintain cGMP and Drug Supply Chain Security Act (DSCSA) compliance, supply through authorized wholesaler networks with established chargeback systems, meet packaging and expiration standards, and provide comprehensive product information including NDC codes and manufacturing locations.

Activity appears concentrated in Texas and Minnesota, with recent RFI and RFP activity from the Texas Health and Human Services Commission and MMCAP. The City of Tampa's April 2026 advanced life support medications IFB (due April 8, 2026, with an estimated contract value of $40,000) represents municipal emergency services demand. The MMCAP RFP for generic pharmaceuticals (due March 26, 2026, effective July 1, 2026) sets a two-year term with optional extensions and is weighted 75 percent on price competitiveness, 10 percent on fixed pricing certainty, and the remainder on administrative compliance and EDI capability. The Texas HHS Commission's April 2026 RFI regarding direct-to-manufacturer prescription programs signals exploratory state-level interest in alternative procurement models outside traditional pharmacy benefit manager and group purchasing organization channels, though no formal award values or timelines are attached to that information-gathering phase. Cooperative purchasing through MMCAP requires vendors to maintain $5,000,000 commercial general liability coverage and absorb a 3 percent administrative fee on all contract purchases.